Chimeric fusion genes are highly prevalent in childhood acute leukemia and have been recognized as causal events in the process of leukemic transformation. Infant leukemia, for example, is characterized by the very frequent occurrence of MLL gene rearrangements. These genetic events are mostly initiated in utero as substantially evidenced by studies of twins with leukemia, retrospective analysis of neonatal blood spots and cord blood screening. 1 The chromosomal translocation t(2;11)(q31;p15) results in the NUP98-HOXD13 (ND13) gene fusion which was first identified in a patient with therapy-related AML.
2 Albeit rare, it is a recurrent event in de novo AML 3 and has also been reported in infant AML. 4, 5 In this report, we identified the third infant diagnosed with AML presenting with ND13. All three patients were diagnosed at highly similar ages, varying from 9-11 months, which might indicate a rapid onset of leukemia development. Based on the yet available information, the ND13 in infants correlates with the phenotype AML-M4 and is associated with a good prognosis. By applying state-of-the-art technologies, 6 the genomic breakpoint sequence was unveiled. This allowed us to screen an archived neonatal blood spot to demonstrate for the first time the presence of a concordant ND13 gene fusion. Detailed methods performed in this study are described in Supplementary Information. A 9-month-old boy was hospitalized in December 2009, with anemia, bruising and hepato-splenomegaly. He presented the first signs of the disease at age of 6 months, when he had an episode of pulmonary infections resistent to antibiotics. Laboratory tests showed hemoglobin 5.7 g/dl, white blood cell count 318 730/mm 3 and platelets count 26 000/mm 3 . The morphology of bone marrow aspiration was suggestive of a myeloproliferative disorder, and flow cytometry analysis demonstrated the cells surface markers expression of CD13, CD14, CD15, CD33, HLA-DR and CD64. These results were consistent with an AML with monocytic differentiation (AML-M4). The G-banded cytogenetic analysis revealed an abnormal karyotype characterized by 46,XY, t(2;11)(q31;p15) in at least 26 metaphase cells. An MLL rearrangement was not identified. The patient has been treated with a standard AML protocol with cytarabine, idarubicin, etoposide and aracetyn substances. After 30 days of the treatment, the myelogram showed morphological complete remission. The patient is currently in treatment maintenance and in clinical remission.
We first confirmed by reverse transcriptase-PCR that the translocation t(2;11) gave rise to a gene fusion transcript between NUP98 and HOXD13 as a 424-bp PCR product in bone marrow cells of the patient at diagnosis (Figure 1a ). Sequence analysis of the PCR amplimer revealed that exon 12 of NUP98 was fused in-frame with exon 2 of HOXD13 (Figure 1c) . The sequence at the junction of the fusion transcript was the same of that reported in previous cases.
2 -5 The fusion mRNA when tested in bone marrow cells at morphological complete remission at day 60 treatment could not be detected anymore.
In addition, we could successfully amplify transcripts that derive from the remaining HOXD13 germline allele (Figure 1b) , although HOXD13 expression is normally not expected in hematopoietic cells. HOXD13 ectopic expression has been a recurrent event in patients with ND13, and occurred in two out of three now described infant patients with this abnormality, 4, 5 Although the mechanism that leads to the ectopic expression of HOXD13 is not fully understood, it has been discovered that induction of FLT3, HOXA7, HOXA9 and other HOX genes underlies the transforming effects of ND13 and may support a common mechanism for leukemogenesis initiated by both NUP98 and MLL gene fusions. 7 We further investigated whether the patient had abnormalities in FLT3, KRAS, NRAS and PTPN11 genes at presentation; however, no genetic abnormality was found.
After cloning the genomic PCR amplimer deriving from the diagnostic sample and subsequent DNA sequencing, 6 the genomic loci of the chromosomal breakpoint ( Figure 1e ) were identified at nucleotide 8850 of NUP98 intron 12 and 3583 nucleotides upstream of HOXD13, thus validating the prior reverse transcriptase-PCR analysis (fusion of NUP98 exon 12 with HOXD13 exon 2). (f) Sequencing analysis of PCR amplimers generated from diagnosis and Guthrie card samples.
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By retrospective screening of neonatal blood spot, we provide in this study evidence that the ND13 gene fusion originated before birth (Figures 1d and f) . PCR primers to amplify ND13 in the neonatal DNA sample were designed according to the diagnostic spanning breakpoint region sequence (Supplementary Table 1 ). Briefly, optimal PCR conditions as well as sensitivity evaluation was established for each specific primer pair using an 1:10 dilution series of leukemic patient DNA sample into the DNA of a healthy individual (Supplementary Figure 1) and, a 1/8 portion of the Guthrie card was used directly in PCR. We included negative controls in all PCR reactions (blank, DNA from leukemia cell line and from healthy individuals) to validate our findings. We further performed a semiquantitative assessment of the size of the clone at birth through a titration PCR experiment. Briefly, we compared DNA log-dilutions from a ND13 plasmid with log dilutions of isolated genomic DNA from patient cells at diagnosis and the corresponding Guthrie card (Supplementary Methods and Figure 2 ). The direct comparison revealed that B1/1.000 patient cells contained the gene fusion at birth. This is in line with previous findings, where the number of pre-leukemic cells present on Guthrie cards has been estimated to be in the range of 1 in 200-4000 cells when the presence of the MLL-AF4 allele has been investigated. 8 However, there are no studies available that correlate the amount of pre-leukemic cells on Guthrie cards with the onset of disease in a given patient. This might be due to the fact that most pre-leukemic clones need secondary genetic hits to develop into a leukemic clone and enable to develop the disease. Presumably, there are only very few exceptions from this rule. Therefore, further studies will be necessary to investigate a potential relationship between the amount of pre-leukemic clones on Guthrie cards, latency of disease onset, amount of leukemic cells at diagnosis leukemia and the presence of specific fusion alleles.
It has been shown that NUP98 is a frequent target of chromosomal aberrations following chemotherapies that inhibit DNA topoisomerase II (topo-II). 9 Our case is already the third example of de novo infant leukemia with NUP98-associated AML, indicating that NUP98 aberrations are involved in infant leukemia. As previously suggested, 5 we also assume that exposure of the fetus to topo-II inhibitors during pregnancy might cause rearrangements of NUP98 through similar pathway of those observed in other infant leukemia and therapy-related AML. The fact that we demonstrated for the first time that this ND13 leukemia derives from a pre-leukemic clone that exists already before birth substantiates epidemiological-molecular studies of more patients with NUP98-associated AML that will be required to verify whether and what kind of maternal exposures may be associated with this event.
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